Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,366

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

December 1, 2026

Conditions
Post-ERCP Pancreatitis
Interventions
DRUG

standard dose indomethacin

Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.

DRUG

low dose indomethacin

Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.

Trial Locations (12)

Unknown

NOT_YET_RECRUITING

Changhai Hospital, Shanghai

RECRUITING

Ruijin Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai General Hospital, Shanghai

NOT_YET_RECRUITING

Affiliated Hospital of Jiaxing University, Zhejiang

NOT_YET_RECRUITING

Dongyang People's Hospital, Zhejiang

NOT_YET_RECRUITING

First Affiliated Hospital of Ningbo University, Zhejiang

NOT_YET_RECRUITING

Jinhua Central Hospital, Zhejiang

NOT_YET_RECRUITING

People's Hospital of Quzhou, Zhejiang

NOT_YET_RECRUITING

Shaoxing People's Hospital, Zhejiang

NOT_YET_RECRUITING

Sir Run Run Shaw Hospital, Zhejiang

NOT_YET_RECRUITING

Taizhou Enze Medical Center Group, Zhejiang

NOT_YET_RECRUITING

Zhuji People's Hospital of Zhejiang Province, Zhejiang

All Listed Sponsors
collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

Shanghai General Hospital, China

OTHER

collaborator

Jinhua Central Hospital

OTHER

collaborator

Taizhou Enze Medical Center Group

OTHER

collaborator

Dongyang People's Hospital

OTHER

collaborator

Shaoxing People's Hospital

OTHER

collaborator

First Affiliated Hospital of Ningbo University

NETWORK

collaborator

Affiliated Hospital of Jiaxing University

OTHER

collaborator

People's Hospital of Quzhou

OTHER

collaborator

Zhuji People's Hospital of Zhejiang Province

OTHER

lead

Changhai Hospital

OTHER